JP2022548869A5 - - Google Patents

Info

Publication number
JP2022548869A5
JP2022548869A5 JP2022516358A JP2022516358A JP2022548869A5 JP 2022548869 A5 JP2022548869 A5 JP 2022548869A5 JP 2022516358 A JP2022516358 A JP 2022516358A JP 2022516358 A JP2022516358 A JP 2022516358A JP 2022548869 A5 JP2022548869 A5 JP 2022548869A5
Authority
JP
Japan
Application number
JP2022516358A
Other languages
Japanese (ja)
Other versions
JPWO2021048809A5 (https=
JP2022548869A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058464 external-priority patent/WO2021048809A1/en
Publication of JP2022548869A publication Critical patent/JP2022548869A/ja
Publication of JP2022548869A5 publication Critical patent/JP2022548869A5/ja
Publication of JPWO2021048809A5 publication Critical patent/JPWO2021048809A5/ja
Pending legal-status Critical Current

Links

JP2022516358A 2019-09-12 2020-09-11 新規な置換スルホキシミン誘導体 Pending JP2022548869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921036803 2019-09-12
IN201921036803 2019-09-12
PCT/IB2020/058464 WO2021048809A1 (en) 2019-09-12 2020-09-11 Novel substituted sulfoximine derivatives

Publications (3)

Publication Number Publication Date
JP2022548869A JP2022548869A (ja) 2022-11-22
JP2022548869A5 true JP2022548869A5 (https=) 2023-08-01
JPWO2021048809A5 JPWO2021048809A5 (https=) 2023-08-01

Family

ID=74866664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516358A Pending JP2022548869A (ja) 2019-09-12 2020-09-11 新規な置換スルホキシミン誘導体

Country Status (5)

Country Link
US (1) US12377070B2 (https=)
EP (1) EP4027986A4 (https=)
JP (1) JP2022548869A (https=)
CN (1) CN114746087A (https=)
WO (1) WO2021048809A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024180521A1 (en) * 2023-03-02 2024-09-06 Zydus Lifesciences Limited Treatment for inflammatory bowel disease
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666506A (en) * 1984-08-08 1987-05-19 E. I. Du Pont De Nemours And Company Herbicidal pyrimidines
US5258406A (en) 1991-12-20 1993-11-02 Eli Lilly And Company Sulfonimidamides
PT1270565E (pt) * 1997-01-29 2004-09-30 Pfizer Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
SI3259253T1 (sl) 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
WO2018225018A1 (en) * 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
EP3668840A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (en) * 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
EP3692020A1 (en) * 2017-10-03 2020-08-12 Inflazome Limited Novel compounds
EA202191968A1 (ru) * 2019-01-14 2021-11-16 Кадила Хелзкэр Лимитед Новые замещенные производные сульфонилмочевины
EP4110058A4 (en) * 2020-02-28 2024-03-20 Zydus Lifesciences Limited Novel substituted sulfonylurea and sulfoximineurea derivatives

Similar Documents

Publication Publication Date Title
JP2022548869A5 (https=)
JP1684218S (https=)
CN306731176S (https=)
CN306726570S (https=)
CN305534933S (https=)
CN305534770S (https=)
CN305533783S (https=)
CN305533521S (https=)
CN305532159S (https=)
CN305532117S (https=)
CN305531865S (https=)
CN305531810S (https=)
CN305531692S (https=)
CN305530798S (https=)
CN305530559S (https=)
CN305530469S (https=)
CN305530406S (https=)
CN305530040S (https=)
CN305528315S (https=)
CN305528063S (https=)
CN306757156S (https=)
CN306756054S (https=)
CN306755553S (https=)
CN306754531S (https=)
CN306754032S (https=)